Literature DB >> 20574165

Frequent hyperphosphorylation of AS160 in breast cancer.

Xiao-Hua Jiang1, Jian-Wen Sun, Ming Xu, Xiao-Fei Jiang, Chun-Fang Liu, Yuan Lu.   

Abstract

Enhanced cellular glucose uptake is a frequent characteristic of malignant cells. The Akt substrate of 160 kDa (AS160) is a newly discovered substrate for the protein kinase AKT and phosphorylation of AS160 (p-AS160) was recently recognized to play an important role in glucose transport. However, studies on AS160 in cancer do not yet exist. The aim of the present study was to investigate the p-AS160 level and its correlation with clinicopathological parameters and various biological markers in breast cancer. Results showed that in breast cancer, phosphorylation of AS160 at the key residue T642 was significantly (p < 0.001) higher than that in normal adjacent tissues. P-AS160 staining was positive in 75 of 81 cases (92.6%), including 32 with weak-(score 1), 31 with moderate-(score 2) and 12 with strong immunoreactivity (score 3). P-AS160 was inversely correlated with patient age (p = 0.041) and positively correlated with tumor size (p = 0.013) and the cell proliferation marker Ki-67 (MIB-1) (p < 0.001). This is the first study of AS160 in cancer. Our results show that AS160 phosphorylation level is frequently increased in breast cancer. These results implicate a possible role of AS160 in human breast tumorigenesis and suggest that p-AS160 might be useful as a marker and a potential novel treatment target for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20574165     DOI: 10.4161/cbt.10.4.12426

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  Development of GLUT4-selective antagonists for multiple myeloma therapy.

Authors:  Changyong Wei; Richa Bajpai; Horrick Sharma; Monique Heitmeier; Atul D Jain; Shannon M Matulis; Ajay K Nooka; Rama K Mishra; Paul W Hruz; Gary E Schiltz; Mala Shanmugam
Journal:  Eur J Med Chem       Date:  2017-08-14       Impact factor: 6.514

2.  AS160 controls eukaryotic cell cycle and proliferation by regulating the CDK inhibitor p21.

Authors:  Pianchou Gongpan; Yanting Lu; Fang Wang; Yuhui Xu; Wenyong Xiong
Journal:  Cell Cycle       Date:  2016-05-06       Impact factor: 4.534

3.  The insulin response integrates increased TGF-β signaling through Akt-induced enhancement of cell surface delivery of TGF-β receptors.

Authors:  Erine H Budi; Baby-Periyanayaki Muthusamy; Rik Derynck
Journal:  Sci Signal       Date:  2015-09-29       Impact factor: 8.192

Review 4.  Regulation of Cancer Cell Behavior by the Small GTPase Rab13.

Authors:  Maria S Ioannou; Peter S McPherson
Journal:  J Biol Chem       Date:  2016-04-04       Impact factor: 5.157

5.  Construction of phosphorylation interaction networks by text mining of full-length articles using the eFIP system.

Authors:  Catalina O Tudor; Karen E Ross; Gang Li; K Vijay-Shanker; Cathy H Wu; Cecilia N Arighi
Journal:  Database (Oxford)       Date:  2015-03-31       Impact factor: 3.451

6.  Clinical and genetic analyses of patients with lateralized overgrowth.

Authors:  Yoon-Myung Kim; Yena Lee; Yunha Choi; In Hee Choi; Sun Hee Heo; Jung Min Choi; Hyo-Sang Do; Ja-Hyun Jang; Mi-Sun Yum; Han-Wook Yoo; Beom Hee Lee
Journal:  BMC Med Genomics       Date:  2022-09-30       Impact factor: 3.622

7.  Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma.

Authors:  Javelin C Cheng; Samuel K McBrayer; Cristian Coarfa; Sevim Dalva-Aydemir; Preethi H Gunaratne; John D Carpten; Jonathan K Keats; Steven T Rosen; Mala Shanmugam
Journal:  Cancer Metab       Date:  2013-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.